Prevalence of baseline and follow-up serum creatinine monitoring among patients initiating ACE inhibitors or angiotensin receptor blockers according to clinical guideline recommendations
| Clinical guidelines | All initiators n=223 814 (100%) | ||||||
|---|---|---|---|---|---|---|---|
| NICE heart failure | NICE MI | NICE/UKRA hypertension | NICE CKD | GP Notebook | Wide baseline interval (≤12-months) | Ideal baseline interval (≤1 month) | |
| Baseline testing | x | x | x | x | x | 169 218 (76%) | 75 476 (34%) |
| +Follow-up test ≤2 weeks* | x | NA | x | x | x | 46 486 (21%) | 19 679 (9%) |
| +Follow-up test ≤3 weeks† | 70 792 (32%) | 30 451 (14%) | |||||
*Follow-up test among those with baseline measurements.
†Sensitivity analysis illustrating the importance of 2-week vs 3-week cut-off interval in follow-up test intervals.
CKD, chronic kidney disease; GP, general practice; MI, myocardial infarction; NA, not applicable; NICE, National Institute for Health and Care Excellence; UKRA, United Kingdom Renal Association.